

Special Issue

Biomarkers of Traumatic Brain Injury

Message from the Guest Editors

With regard to the circulating protein biomarkers of traumatic brain injury (TBI), while some breakthroughs have recently been made in the field of diagnostic biomarkers (the implementation of the S100B protein to the Scandinavian guideline as a diagnostic tool for mild TBI and FDA clearance for the Banyan Brain Trauma Indicator Kit (GFAP + UCH-L1) for the diagnosis of mTBI in the USA) and recent studies have confirmed the prognostic power of the most commonly investigated biomarker molecules, there are still lots of uncertainties even regarding the exact diagnostic and/or prognostic capabilities of these few thus far relatively well-characterized/identified molecules. From a broad perspective, there is still a clear unmet clinical need for efficient diagnostic, prognostic, monitoring, etc., biomarkers or biomarker combinations which could enhance the treatment as well as the long-term rehabilitation of TBI patients. In light of this, our current Special Issue is open for the submission of any manuscripts which include clinical as well as experimental observations regarding biomarkers (primarily—but not restricted to—protein biomarkers) of traumatic brain injury.

Guest Editors

Dr. Endre Czeiter

1. Department of Neurosurgery, Medical School, University of Pecs, H-7623 Pecs, Hungary
2. Neurotrauma Research Group, Szentagothai Research Centre, University of Pecs, H-7624 Pecs, Hungary
3. ELKH-PTE Clinical Neuroscience MR Research Group, H-7623 Pecs, Hungary

Dr. Krisztina Amrein

1. Department of Neurosurgery, Medical School, University of Pecs, H-7623 Pecs, Hungary
2. Neurotrauma Research Group, Szentagothai Research Centre, University of Pecs, H-7624 Pecs, Hungary
3. ELKH-PTE Clinical Neuroscience MR Research Group, H-7623 Pecs, Hungary

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/176493

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).